BIOTISSUE OCULAR INC.
MIAMI, FLORIDA

BIOTISSUE OCULAR INC., Miami
BIO-TISSUE, INC.

prides itself on developing products that meet the highest clinical standards, are based on quality research and scientific data, and provide innovative solutions for a range of ocular surface and lid margin diseases. Bio-Tissue prides itself on developing products that meet the highest clinical standards, are based on quality research and scientific data, and provide innovative solutions for a range of ocular surface and lid margin diseases. Bio-Tissue regenerative healing products For more than 30 years, I have been dedicated to making a positive difference in the lives of my patients. Like you, I am passionate about ensuring that my patients enjoy healthy eyes, improved vision, and a better quality of life. process as a platform technology for the treatment of ocular surface diseases. Since its inception, Amy has carried this mission, building Bio-Tissue through impressive levels of annual growth. In addition to her instrumental role in founding the company, Amy continues to lead and drive the company not only to provide the highest quality product possible, but also to continuously improve methods of wound care management. process to preserve the natural wound healing properties of amniotic membrane for ocular surface reconstruction and wound healing. His research focus during the last 30 years has been to identify the active biological components of human amniotic membrane, to develop alternative products to deliver the efficacy of their natural healing properties, and to expand the benefits of its clinical applications. Dr. Scheffer C. G. Tseng received his MD at National Taiwan University and his PhD in Experimental Pathology at the University of California, San Francisco. He completed his residency for Ophthalmology at the Wilmer Eye Institute at Johns Hopkins and his fellowship in Cornea and External Diseases at Massachusetts Eye and Ear Infirmary. Before he joined the Company, he was a Chair Professor at Bascom Palmer Eye Institute, University of Miami School of Medicine. Michael is an accomplished financial executive with over 25 years of experience in public accounting with public and private corporations. Most recently, he was the CFO of a start-up medical device company he co-founded. Prior to that, Mike was the CFO of Stiefel Laboratories, the largest privately-held dermatology company in the world, before it was acquired by Glaxo Smith Klein in 2009. Mike joined Stiefel in 1999 and rose to the leading position of its global financial operations in 2005. He was an integral member of the executive leadership team providing global strategic and operational direction. Michael Cornelius received his Bachelor of Science in Business Administration from Indiana University of Pennsylvania, and he is a CPA with a strong international tax background.  Vision, Mission and Values Company Vision – ‘To be the leader in the regenerative biomaterial industry.’ In the coming 5 years, we envision that TissueTech will be the leader in the regenerative biomaterial industry, based on our superior platform technology, our constant scientific discoveries, and our commitment to continuously build the commercial infrastructure. Over 18 years ago, we entered into ophthalmology as the first company in the medical community to introduce the utilization of amniotic membrane and umbilical cord as regenerative biomaterials, preserving their anti-scarring, anti-inflammatory, and pro-wound healing therapeutic actions with our patented CryoTek™ Method. Today, the medical community has accepted our technology as the standard of care in treating many diseases. As the market heats up and competition increases, we plan to stay ahead of the curve by expanding our clinical uses and overcoming regulatory and reimbursement barriers. We believe TissueTech™ is currently among the top three companies in the regenerative biomaterial industry. Based on our edge in scientific and clinical knowledge and our commitment to invest in our technology, we see TissueTech™ at the forefront of this evolving industry within 5 years. Company Mission – ‘To deliver innovative products of human origin for regenerative healing’. Our scientists discovered the abundant biological properties in human amniotic membrane and umbilical cord tissue that can stimulate regenerative healing. It is our mission to deliver the therapeutic benefits of this tissue by developing innovative and high quality products for different disease indications. To provide guidance as to how we behave and conduct our business, our Executive Leadership Team developed the following principles: Place patients first with high quality products and services. Foster mutual respect to help people reach their potential. formula is the key ingredient 4-Terpineol, the most important organic component of tea tree oil, which helps to keep the eyelids clean and healthy while leaving the user with a cooling sensation on their face. towelettes are all natural, preservative-free lid, lash and facial cleansers that help manage symptoms associated with blepharitis, MGD, rosacea, dry eye, demodex, chalazia and other lid margin diseases. Cliradex towelettes are the #1 doctor recommended solution for ocular hygiene and dry, irritated eyes, and are safe to use everyday. Cliradex comes in a 3” x 2.5” x 3.75” carton containing 24 individually packaged single use towelettes. foaming cleanser, a new refreshing, soothing, and gentle product in eyelid hygiene, is specifically formulated for patients with dry eyes, blepharitis, and MGD. Cliradex® Light works by safely and effectively cleaning microorganisms and debris from eyelids and is meant to be part of a daily hygiene routine. Cliradex Light comes in a foaming dispenser canister intended for 30 days of use and should be stored at room temperature. The statements contained herein have not been evaluated nor approved by the US Food and Drug Administration. Any advice and/or product(s) mentioned should not be used to diagnose, treat, cure, or prevent any disease. Always consult your healthcare professional if you are currently taking medication, pregnant, trying to get pregnant, nursing, or if you have any other health condition before taking any products mentioned or applying any information contained herein.

KEY FACTS ABOUT BIOTISSUE OCULAR INC.

Company name
BIOTISSUE OCULAR INC.
Status
Active
Filed Number
P97000029401
FEI Number
65-0742529
Date of Incorporation
March 28, 1997
Age - 28 years
Home State
FL
Company Type
Domestic for Profit

CONTACTS

Website
http://biotissue.com
Phones
(888) 296-8858
(305) 412-4429
(305) 412-4430

BIOTISSUE OCULAR INC. NEAR ME

Principal Address
7300 corporate center drive,
Ste 700,
Miami,
FL,
33126,
US

See Also

Officers and Directors

The BIOTISSUE OCULAR INC. managed by the three persons from Miami on following positions: Dire

Robert White

Position
Dire Active
From
Miami, 33126

Shaunak Parikh

Position
Dire Active
From
Miami, 33126

Scheffer Tseng

Position
Dire Active
From
Miami, 33126





Registered Agent is CT CORPORATION SYSTEM

Address
1200 SOUTH PINE ISLAND ROAD, PLANTATION, FL, 33324

Events

October 20, 2022
NAME CHANGE AMENDMENT

Annual Reports

2023
March 8, 2023
2022
July 11, 2022